Intended for healthcare professionals

Rapid response to:


Bringing Vioxx back to market

BMJ 2018; 360 doi: (Published 25 January 2018) Cite this as: BMJ 2018;360:k242

Rapid Response:

Re: Bringing Vioxx back to market

If the drug company Tremeau Pharmaceuticals does obtain permission to resurrect Vioxx (rofecoxib) for the relief of severe joint pain caused by Hamophilia, increased cardiovascular risk should be the least of its worries. Other seemingly unanticipated side effects will be of more importance including death from cerebral and gastrointestinal haemorrhage and disability from epistaxes, urinary bleeding and haemarthroses. It is possibly an outcome not even considered by the drug company that the Vioxx, used to treat the pain from haemarthroses due to Haemophilia, may actually produce haemarthroses. If some of the drug company executives are considering travelling to Britain for the wedding in May, they should know that anyone who promotes the use of a non steroidal ant-inflammatory drug as an analgesic in someone with severe Haemophilia risks being put in the Tower of London. J.L.Raven

Competing interests: No competing interests

04 March 2018
John L Raven
Retired Haematologist
77 View Terrace. East Fremantle, WA 6158, Australia